Effectiveness of Ferritin-guided Donation Intervals in Blood Donors: results of the Stepped Wedge Cluster-randomised FIND’EM Trial

Introduction

Annually, more than 100 million whole blood donations are made worldwide to provide life-saving treatment for patients requiring transfusion (1). However, whole blood donors that donate repeatedly are at risk of developing iron deficiency and subsequent anemia (2). Male donors lose approximately 8% of their total iron stores with each whole blood donation, whereas menstruating women can lose up to 81% of their total iron stores (3–5). Iron stores can be monitored through measuring ferritin levels. Iron deficiency, defined as ferritin levels <15 ng/ml, is present in approximately 15.0% of female and 9.4% of male Dutch repeat donors (6).

There is no consensus on strategies for donor iron management to ensure donor health. Currently, two main strategies are being used to prevent iron deficiency in whole blood donors: extending donation intervals or providing iron supplements (7–9). Negative perceptions regarding iron supplementation, adverse effects like gastrointestinal disturbances, and poor compliance could be reasons to prefer extended donation intervals over iron supplementation (9,10). In previous studies, extended donation intervals were associated with lower risk of Hb deferrals (11,12). The randomized-controlled INTERVAL trial showed that donation intervals of 12 and 16 weeks for men and women, respectively, leads to significantly higher Hb and ferritin levels compared to intervals of 8 and 12 weeks (12). Most blood establishments have implemented an Hb-based monitoring policy to protect donor health, prevent anemia and ensure a sufficient Hb content in the product, deferring blood donors with Hb levels below 13.5 g/dL (males) or 12.5 g/dL (females) (7–9,13–15). However, iron deficiency can present without low Hb, especially in repeat donors. As Hb levels do not reflect iron stores, the current standard of Hb monitoring is insufficient to ensure the maintenance of proper iron reserves and donor health. The World Health Organization (WHO) advises additional monitoring of ferritin in donors to detect iron deficiency and monitor donor health (16).

In 2017, a new nationwide policy for iron monitoring of whole blood donors was implemented by Sanquin Blood Bank in The Netherlands. In addition to the existing capillary Hb measurement at the pre-donation screening, a ferritin measurement is conducted in venous samples at the first donation of new donors and after every fifth whole blood donation of repeat donors. If ferritin levels are between 15 and 30 ng/mL or below 15 ng/mL, the subsequent donation interval is extended to six or twelve months, respectively. A stepped-wedge approach, with random cross-over of blood collection centers from the existing to the new policy, was used to evaluate the effects of this ferritin-guided donation interval policy for whole blood donors on (1) Hb and ferritin levels, (2) iron deficiency, (3) Hb deferral, (4) donor return rates, and (5) self-reported iron deficiency-related symptoms.

Methods

Results

A total of 412,888 whole blood donors made 1,634,700 donations during the study and implementation period. We performed additional measurements in samples of 37,621 donations by 36,099 donors (Figure 1). Table 1 shows the baseline characteristics of participating donors by sex and randomization group. Overall, across the randomization groups, donors were well balanced with respect to characteristics and comparable with the general donor population (Table 1)(23). Baseline characteristics of the 7,573 participants in the questionnaire are provided in Table S1.

• Download figure
• Open in new tab

Figure 2 shows that, in all groups, the prevalence of both iron deficiency and Hb deferral decreased during trial. Ferritin-guided donation intervals are associated with significantly higher ferritin and Hb levels and less iron deficiency and Hb deferrals (Table 2). Compared to pre-implementation, the intervention was associated with up to 0.56 log-transformed ng/mL higher ferritin and 0.39 g/dL higher Hb at 36 months after implementation in males (Table 2). In both premenopausal and postmenopausal females, we also observe positive associations, albeit smaller, with an increasing trend over time since implementation. Moreover, at 36 months after implementation, the odds ratio of 0.19 indicates that males are 81% less likely to be iron deficient than at pre-implementation (Table 2). In postmenopausal females, odds ratios also decrease over the course of the trial, with iron deficiency being 87% less likely at 36 months after implementation as compared to pre-implementation (Table 2). Hb deferral in males was up to 73% less likely as time since implementation increased, compared to pre-implementation. Similarly, in premenopausal females, Hb deferral is up to 35% less likely at full implementation than at pre-implementation (Table 2). In postmenopausal females, Hb deferral is up to 49% less likely than at pre-implementation.

• Download figure
• Open in new tab

The odds for donors to return within six months of the first allowed donation date are lower at each timepoint after implementation compared to pre-implementation (Table 2). At 36 months after implementation, males were 43% less likely to return for donation (Table 2). For premenopausal females, we do not observe a clear decrease in odds over the course of the trial, while for postmenopausal females, the odds to return for a donation do decrease but are not statistically significant at all timepoints (Table 2). Table S2 shows that after implementation odds for return are mostly lower in donors with ferritin levels ≤30 compared to donors with ferritin > 30 ng/mL. However, there is no significant difference between the two groups: confidence intervals overlap at most timepoints.

There was no evidence of improvement of self-reported iron deficiency-related outcomes after implementation of the new policy. There were no consistent significant patterns for pica, fatigue, cognitive functioning, the SF-36, and warm glow (Table 3). However, the reporting of RLS increased. Compared to pre-implementation, premenopausal females, postmenopausal females, and males were 185%, 111%, and 106% more likely to report RLS at 24 months after implementation than at pre-implementation.

Discussion

Our stepped-wedge cluster-randomized trial among Dutch whole blood donors shows that ferritin and Hb levels are significantly higher and iron deficiency and Hb deferral prevalence significantly lower after the implementation of ferritin-guided donation intervals in comparison to the prior standard of Hb monitoring only. Conversely, we found that the odds for donor return within six months decreased substantially after implementation of this policy. The new policy did not affect most self-reported iron deficiency related symptoms, but was associated with increased reporting of RLS.

The new policy was associated with being significantly less likely to be iron deficient and higher ferritin and Hb levels compared to pre-implementation, which aligns with findings in donor population simulations that assess the impact of ferritin testing (24). A possible explanation for the weaker effects in premenopausal females compared to other groups may be that already at pre-implementation, premenopausal females were more frequently deferred, a measure of a similar nature that is part of the pre-implementation Hb monitoring policy, and return less. This allows more recovery time from donations. Additionally, because of more stable iron stores due to the healthy donor effect, their lower donation frequency and baseline ferritin levels, the remaining pool of premenopausal donors may not show associations as strong as the other groups (25,26).

Our finding that the new policy is associated with significantly lower odds for donor return supports previous findings on the effects of deferral on donor return, but may additionally be explained by the negative effects of the COVID-19 pandemic on blood donation intentions (27–30). Return within six months for donors measured during both weeks at full implementation overlapped with lockdowns due to the COVID-19 pandemic in The Netherlands. However, the negative association of the new policy with donor return in premenopausal females was weaker compared to other groups, which may be explained by their exposure to more frequent deferral through the old Hb monitoring policy.

The increased reporting of RLS seems surprising, but may simply be a result of an increased awareness as a result of information provided to the donor upon implementation. Further investigation shows no statistically significant correlation between RLS and ferritin levels. The lack of improvement we found in self-reported iron deficiency-related symptoms aligns with previous randomized placebo-controlled trials investigating the effects of iron repletion, albeit through iron supplementation, on self-reported donor health (31–33). In addition, the steady reduction in iron deficiency and Hb deferral may have delayed positive effects on self-reported iron deficiency-related symptoms, which would require longer follow-up in future studies.

Our findings raise important policy and practical considerations. First, our results suggest that a ferritin-guided donation interval policy effectively reduces iron deficiency and Hb deferral in whole blood donors. This supports the WHO’s advice to conduct additional monitoring of ferritin to detect iron deficiency and monitor donor health (16). Furthermore, it provides policymakers with a monitoring option that requires no effort from blood donors, may be more effective in protecting donor’s iron status than standard Hb monitoring practices and does not impose a risk of side effects as related to iron supplementation (10). However, the decreasing odds of donor return stresses the need for intensified efforts to retain donors after implementation of this policy, specifically in donors whose intervals were extended. We encourage intensified donor recruitment with the implementation of prolonged donation intervals to ensure the continuity of the blood supply, because of the effects on donor return and decreased donor availability due to the prolonged donation intervals (34). Iron supplementation can be considered as an alternative or additional strategy, as it may involve less deferral and extended donation intervals and thus benefit donor availability (24,35). Nevertheless, there are also long-term benefits to a ferritin-guided donation interval policy: initial evaluations and the results presented here suggests that donors subjected to this policy might be deferred less often on site and are less likely to discontinue their donor career, resulting in a more stable donor pool (34).

To our knowledge, this is the first randomized study that goes beyond the limitations of Hb monitoring by evaluating the effectiveness of ferritin-guided donation intervals in improving Hb and ferritin levels, donor return rates and decreasing iron deficiency, Hb deferrals, and iron deficiency-related symptoms. One of the major strengths of this trial is the stepped wedge cluster-randomized approach as it allows simultaneous implementation and evaluation of a new policy. However, there are also limitations to this study. The nature of the intervention poses a risk of overestimating the positive effect of ferritin-guided donation intervals. Donors with low ferritin, whose donation intervals are extended, may not return frequently, potentially resulting in selection bias. However, the risk of overestimation is to some extent minimized as the duration of the trial exceeds the length of extended donation intervals. There may even be underestimation of the effect on iron deficiency, as cut-offs for iron deficiency used in this study are lower than suggested in literature (36,37). Furthermore, even though donor loss may be detrimental for the blood supply, extended intervals could be beneficial for the health of donors struggling to maintain sufficient iron levels. There may also be more delayed effects of this trial, because ferritin levels are measured once every five donations, which delays individual donors’ actual encounter with the policy.

The FIND’EM study provides substantial evidence that ferritin-guided donation intervals increase Hb and ferritin levels and thereby effectively prevent iron deficiency and Hb deferral. Further efforts are needed to counteract the negative effects on donor return and to investigate long-term effects on donor health outcomes. Our results may help blood services worldwide to improve their donor iron management policies in order to protect donors from developing iron deficiency.

Declarations

Authors’ contributions

KvdH designed the study. KvdH, MS, FP and FQ set up and coordinated data collection. AM, and SR wrote the analysis plan and drafted the manuscript. AM, SR and FP conducted the analyses with support from EH. The manuscript was critically reviewed and approved by all co-authors.